Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia

NCT01222143 | Terminated Phase 1 DMC

• 1 other identifier: CAMN107YCA03T
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is a phase I/II open-label study that is evaluating the toxicity and efficacy of nilotinib combined with mitoxantrone, etoposide, and high-dose cytarabine (NOVE-HiDAC) chemotherapy for patients with poor-risk acute myeloid leukemia (AML). There are two parts to the study. The first part (Phase I) will determine the maximum dose of nilotinib that can safely be given when combined with NOVE-HiDAC. This dose will then be used in combination with the NOVE-HiDAC regimen in the second part of the study (Phase II), which will evaluate the antileukemic activity of the treatment. The patients who achieve complete remission from the induction therapy (1 cycle) will then receive consolidation therapy combined with nilotinib (maximum of 2 cycles). The patient population for this study will have AML and will fall into a poor risk category. This means they have persistent leukemia after induction therapy, they relapse within two years of achieving complete remission with induction therapy, or they have certain poor risk features at diagnosis. The AML cells will also be positive for c-kit (a stem cell factor receptor), which is involved in cancer cell growth. Nilotinib is a drug that blocks the effects of c-kit. Using this drug in combination with chemotherapy may improve ability of the chemotherapy drugs to kill leukemia cells. This may then increase the chances of the leukemia going into complete remission.

Conditions

Acute Myeloid Leukemia

Keywords

AML; NOVE-HiDAC; Nilotinib

Outcome Measures

Primary Outcomes (3)

• To determine the maximum tolerated dose (MTD) of nilotinib when combined with the NOVE-HiDAC regimen (mitoxantrone, etoposide, and modified high-dose cytarabine).

  To determine the maximum tolerated dose (MTD) of nilotinib combined with mitoxantrone, etoposide, and modified high-dose cytarabine (NOVE-HiDAC) induction chemotherapy followed by consolidation chemotherapy for patients with poor risk c-kit positive AML.

  2 years

• To evaluate the toxicity of the treatment regimen.

  2 years

• To determine the complete response (CR) rate of this combination at the maximum tolerate dose (MTD) of nilotinib.

  2 years

Secondary Outcomes (5)

• To determine the disease-free survival of this combination.

  2 years

• To evaluate the pharmacodynamic effects of nilotinib on pERK and pAKT (phosphorylated ERK and AKT) in AML cells in vivo.

  2 years

• To correlate clinical responses with the degree of pAKT and pERK inhibition achieved in vivo.

  2 years

• To correlate the degree of pAKT and pERK inhibition with nilotinib pharmacokinetics.

  2 years

• To correlate pAKT and pERK inhibition with c-kit mutations.

  2 years

Study Arms (1)

NOVE-HiDAC and Nilotinib

EXPERIMENTAL

All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.

Drug: NOVE-HiDAC; Drug: Nilotinib

Interventions

NOVE-HiDAC DRUG

NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12. During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10.

NOVE-HiDAC and Nilotinib

Nilotinib DRUG

The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study. During induction, nilotinib will be given orally on Days 1-12. During consolidation, nilotinib will be given orally on Days 1-10.

NOVE-HiDAC and Nilotinib

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• AML as defined by WHO (World Health Organization) criteria, all subtypes except APL (acute promyelocytic leukemia).
• One of the following poor risk features:
• Persistent leukemia (at least 10% bone marrow blasts) after induction therapy, consisting of cytarabine 100-200 mg/m2 plus an anthracycline.
• Relapse within two years of achieving complete remission with such induction therapy. Any consolidation therapy is acceptable, including stem cell transplantation.
• No prior inductions, but antecedent myeloproliferative disorder or CMML (chronic myelomonocytic leukemia) (These patients are given NOVE-HiDAC as frontline therapy at Princess Margaret Hospital).
• Positivity for c-kit (CD117) in at least 30% of blasts as measured by flow cytometry. For relapsed patients, this will be assessed at the time of relapse. For primary induction failures the initial diagnostic sample may be used.
• Age 18-65.
• ECOG performance status \< 3 (see Appendix I).
• Patients must have the following laboratory values within normal limits (WNL) at the local institution lab or corrected to WNL with supplements prior to first dose of study medication.
• Potassium (WNL)
• Magnesium (WNL)
• No chemotherapy within the previous four weeks, other than hydroxyurea to control counts. Hydroxyurea may be continued up to Day 4 of treatment with nilotinib. If hydroxyurea is used, it must be stopped at least 48 hours prior to starting chemotherapy.
• Able to give informed consent.

You may not qualify if:

• Active uncontrolled infection.
• Active CNS (central nervous system) leukemia
• Serum creatinine \> 200 umol/L.
• Serum bilirubin \> 1.5 x ULN, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) \> 2x ULN (upper limit of normal).
• Serum amylase and lipase \> 1.5x ULN
• Left ventricular ejection fraction \< 50%
• Impaired cardiac function including any of the following:
• Long QT syndrome or a known family history of long QT syndrome
• History or presence of clinically significant ventricular or atrial tachyarrhythmias
• Clinically significant resting bradycardia (\< 50 beats per minute)
• Inability to monitor the QT interval by ECG
• QTc \> 450 msec on baseline ECG (electrocardiogram). If QTc \> 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
• Myocardial infarction within 1 year of starting study drug
• Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
• Patients currently receiving treatment with strong CYP3A4 inhibitors as listed in Section 5.8 and treatment cannot be either discontinued or switched to a different medication prior to starting study drug.

Sponsors & Collaborators

• University Health Network, Toronto: lead
• Novartis Pharmaceuticals: collaborator

Study Sites (1)

Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

nilotinib

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Joseph M Brandwein, MD, FRCPC

  Princess Margaret Hospital, Canada

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2010
• First Posted: October 18, 2010
• Study Start: October 1, 2010
• Primary Completion: April 1, 2015
• Study Completion: April 1, 2015
• Last Updated: June 22, 2015

Record last verified: 2015-06

Locations

CA (1)